Clinical Trials Logo

Clinical Trial Summary

A randomized, controlled, double-blind, clinical trial will be conducted to study the evaluate the effect of blue light combined with corticoid treatment in the preoperative and postoperative period of keloid removal surgery.


Clinical Trial Description

Keloid scars are characterized by the excessive proliferation of fibroblasts and an imbalance between the production and degradation of collagen, leading to its buildup in the dermis. Although the genesis of this condition is not yet fully clarified, keloids are known to have a genetic component and are related to an increase in the expression of transforming growth factor beta (TGF-β). There is no "gold standard" treatment and recurrence is frequent. Therefore, novel treatment options are needed. In vitro studies have demonstrated that photobiomodulation (PBM) reduces the multiplication velocity and quantity of fibroblasts as well as the expression of TGF-β. This is a low-cost, noninvasive therapy with no side effects that has proved to be a good tool to complement the most established treatment. Therefore, the purpose of this study is to evaluate the effect of blue light combined with corticoid treatment in the preoperative and postoperative period of keloid removal surgery. A randomized, controlled, double-blind, clinical trial will be conducted involving two groups: 1) Sham (N = 29): intralesional administration of corticoid (IAC) and sham PBM in the preoperative and postoperative periods of keloid removal surgery; and 2) active PBM combined with IAC (N = 29) in the preoperative and postoperative periods of keloid removal surgery. Transcutaneous PBM will be performed on the keloid in the preoperative period and on the remaining scar in the postoperative period using blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J). The patients will answer two questionnaires: one for the assessment of quality of life (Qualifibro-UNIFESP) and one for the assessment of satisfaction with the scar (PSAQ). The team of plastic surgeons will answer the Vancouver Scar Scale (VSS). All questionnaires will be administered one, three, six, and twelve months postoperatively. The keloids will be molded in silicone prior to the onset of treatment and prior to excision to assess pre-treatment and post-treatment size. The same will be performed for the remaining scar at one, three, six, and twelve months postoperatively. The removed keloid will be sent for histopathological analysis for the determination of the quantity of fibroblasts, the organization and distribution of collagen (picrosirius staining), and the expression of TGF-β. All data will be submitted to statistical analysis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04824612
Study type Interventional
Source University of Nove de Julho
Contact
Status Enrolling by invitation
Phase N/A
Start date August 30, 2021
Completion date January 2024

See also
  Status Clinical Trial Phase
Recruiting NCT02923596 - Retrospective Study of Keloid Disorder N/A
Completed NCT02922972 - Treatment of Keloid Scar by Autologous Platelet Rich Plasma Obtained With RgenKit-BCT N/A
Terminated NCT01478243 - Study of Psycho-Social Impact of Keloid N/A
Recruiting NCT01423383 - Epidemiology Study of Keloid N/A
Completed NCT03228693 - Gene Expression and Biomarker Profiling of Keloid Skin N/A
Not yet recruiting NCT04326959 - Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Phase 1/Phase 2
Recruiting NCT03312166 - Compressive Device to Prevent Keloïd Scars Recurrence [SCARWARS] N/A
Recruiting NCT02823236 - Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars Phase 3
Recruiting NCT04597060 - The Safety and Efficacy of Thermo-mechanical System for Fractional Ablation Associated Triamcinolone Acetonide Drug Delivery for the Treatment of Hypertrophic Scars and Keloids N/A
Completed NCT05887804 - Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial Phase 4
Completed NCT05939817 - The Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial Phase 4
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Completed NCT04169438 - Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions N/A
Recruiting NCT01423981 - Web Based Investigation of Natural History of Keloid Disorder, an Online Survey N/A
Completed NCT01446770 - Evaluation of the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181 Phase 2
Recruiting NCT06138964 - Comparing the Effect of siSPARC Microneedle Patch Versus siSPARC+siLR4A Microneedle Patch on Post-surgical Scars Phase 3
Enrolling by invitation NCT05461157 - Preoperative Silicone Ointment and Wound Healing N/A
Not yet recruiting NCT04593706 - Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) N/A
Active, not recruiting NCT04988022 - Dupilumab in the Treatment of Keloids Phase 4
Withdrawn NCT02546076 - Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars Phase 2